Suchergebnisse - "Schmid, Peter"

PubPharm (22)

1

XENERA-1 : a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease

enthalten in: Breast cancer research : BCR | 2023

von Schmid, P. | Cortes, J. | Joaquim, A. | +13

2

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT) : a randomised phase II study

enthalten in: Breast cancer research and treatment | 2023

von Oswald, A. | Symeonides, S. | Wheatley, D. | +16

3

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer : A Detailed Safety Analysis of the Randomized PARSIFAL Trial

enthalten in: The oncologist | 2023

von Di Cosimo, S. | Pérez-García, J. | Bellet, M. | +20

4

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Llombart-Cussac, A. | Pérez-García, J. | Bellet, M. | +52

ErratumIn: JAMA Oncol. 2021 Nov 1;7(11):1729. - PMID 34792545

5

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

6

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pérez-García, J. | Llombart-Cussac, A. | G Cortés, M. | +16

7

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

enthalten in: Breast cancer research : BCR | 2021

von Schmid, P. | Sablin, M. | Bergh, J. | +17

8

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

enthalten in: The New England journal of medicine | 2020

von Modi, S. | Saura, C. | Yamashita, T. | +99

CommentIn: Cancer Discov. 2020 Feb;10(2):167. - PMID 31843763

9

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer : The PAKT Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Schmid, P. | Abraham, J. | Chan, S. | +26

CommentIn: Nat Rev Clin Oncol. 2020 Mar;17(3):135. - PMID 31900440

10

FIR : Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Spigel, D. | Chaft, J. | Gettinger, S. | +11